2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 243-245
Treatment Considerations, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Clinical Practice (Health Services and Quality), Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Clinical Research, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

1092 Fatigue severity is associated with progressive impairment in quality of life in chronic primary immune thrombocytopenia: A real-world prospective study evaluating meaningful severity categories for FACIT-fatigue

Sandhya Panch, MD, Nichola Cooper, MD, FRCP, FRCPath, MA2, Caroline Piatek, MD3, Jérôme Msihid, MSc4, Nancy El-Hoyek, PharmD, MSc5, Ahmed Daak, MD, PhD, MBA6, Julie Kissell, PhD7, Maria Belen Rodriguez, MD8, Howard A Liebman, MD9, David J Kuter, MD, DPhil10
1 University of Washington, Seattle, Washington, United States
2 Hammersmith Hospital, London, United Kingdom
3 University of Southern California, Los Angeles, California, United States
4 Sanofi, Gentilly, France
5 Sanofi, Cambridge, Massachusetts, United States
6 Sanofi, Cambridge, Massachusetts, United States
7 Sanofi, Cambridge, Massachusetts, United States
8 Sanofi, Cambridge, Massachusetts, United States
9 University of Southern California, Los Angeles, California, United States
10 Massachusetts General Hospital, Boston, Massachusetts, United States

BACKGROUND: Primary immune thrombocytopenia (ITP) is a rare disease characterized by complex immune dysregulation, chronic inflammation, and increased destruction and impaired production of platelets, resulting in bleeding, thrombosis, cognitive impairment, and psychological distress. Fatigue is a prevalent, bothersome symptom of ITP among patients; however, its severity and impact on quality of life (QoL) have not been well characterized. Although the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale is widely used to assess fatigue across diseases, clinically meaningful severity thresholds have not been established in ITP. This study characterized fatigue severity in patients with chronic ITP by deriving meaningful score regions (MSRs) for the FACIT-Fatigue total score and investigated the relationship between fatigue severity and the ITP-Patient Assessment Questionnaire (ITP-PAQ) domains.

METHODS: This observational, prospective, cross-sectional study was conducted in the United States and the United Kingdom among adult patients (aged ≥18 years) with chronic primary ITP (>1 year) who had achieved an initial response to first-line therapy and were either receiving advanced ITP treatment, regardless of platelet counts (PC), or were in remission/observation without treatment for ≤1 year. The FACIT-Fatigue (0–52; lower score=greater fatigue) MSRs were derived using the ITP-PAQ item 10 (physical fatigue; lower score=lower QoL; Likert scale: 1=all the time to 5=never) as an anchor. Anchor adequacy was assessed using Spearman correlation (ρ), and MSRs were defined using descriptive statistics across anchor categories. Fatigue severity was assessed overall and across subgroups, and its relationship with the ITP-PAQ domains was evaluated descriptively.

RESULTS: Total 97 patients (median age: 54.0 years, 65.0% female, median ITP duration: 10.0 years, median [Q1–Q3] PC: 143×109/L [85–222×109/L]) completed the FACIT-Fatigue questionnaire (median [Q1–Q3] score: 40.0 [30.0–46.0]) and the ITP-PAQ item 10. The FACIT-Fatigue score was strongly correlated with the ITP-PAQ item 10 (ρ = 0.72) and showed a monotonic gradient across item 10 categories, validating its use as an anchor. Four MSRs for the FACIT-Fatigue were defined: severe fatigue (0–25), moderate fatigue (26–38), mild fatigue (39–45), and no fatigue (46–52), resulting in 18.6%, 24.7%, 29.9%, and 26.8% patients in the cohort, respectively. Moderate-to-severe fatigue was more common among female than male patients (49.2% [31/63] vs 32.4% [11/34]) and was reported in 39.1% (9/23), 57.8% (26/45), and 24.1% (7/29) of patients aged 20–40 years, >40–65 years, and >65 years, respectively. Across PC categories, moderate-to-severe fatigue was observed in 41.7% (5/12), 36.4% (8/22), and 45.2% (28/62) of patients with PC <50x109/L, 50–<100x109/L, and ≥100x109/L, respectively, indicating that clinically significant fatigue persisted irrespective of adequate PCs. Across disease-duration categories (1–<5 years; 5–<15 years; ≥15 years), the prevalence of moderate-to-severe fatigue ranged between 38.7% and 53.3%; it was reported in 38.8% (26/67) and 27.8% (5/18) of patients receiving thrombopoietin receptor agonists and corticosteroids, respectively. Moderate-to-severe fatigue was also observed in 47.1% (8/17) and 60.0% (6/10) of patients with anxiety and depression, respectively, and in 42.5% (34/80) and 41.4% (36/87) of those without these comorbidities. All ITP-PAQ domains (0–100) demonstrated a clear response-gradient across FACIT-Fatigue severity categories, with progressively lower scores from no fatigue to severe fatigue categories. Large numerical differences were observed in Sleep/Fatigue (mean score [SD]: 90.4 [13.6], 79.1 [17.0], 65.4 [19.0], 36.8 [20.1], Physical Health-Bother (93.8 [7.2], 85.7 [17.2], 81.5 [15.9], 42.9 [30.0]), overall QoL (84.1 [18.0], 67.5 [20.7], 65.4 [20.1], 33.1 [23.2]), and Psychological Health (92.1 [10.4], 84.6 [16.2], 72.5 [23.3], 43.3 [29.7]).  

CONCLUSIONS: Clinically meaningful FACIT-Fatigue severity categories were established in chronic ITP using the ITP-PAQ item 10, and strong correlation supported its validity to assess physical fatigue in ITP. Moderate-to-severe fatigue was common across patient subgroups, regardless of PC or treatments. Increasing fatigue severity corresponded to progressively worse QoL across the ITP-PAQ domains, highlighting fatigue as a critical patient-centered outcome in chronic ITP.

Sandhya Panch, MD: Novartis - Honoraria; Sobi - Honoraria; Sanofi - Honoraria; Amgen, Argenyx, J&J, Novartis, Sanofi, Sobi, and Recordati - Research Funding; Incyte, Novartis, Uoro Med., Sanofi, SOBI, and Takeda - Research Funding; Amgen, Argenyx, J&J, Novartis, Sanofi, Sobi, and Recordati - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)